Why Eli Lilly Stock Slumped Today

A rival just cut the price of a competing medication. This puts the list price of weight-loss drug Zepbound under pressure.

The Motley Fool • 4 hours ago

Novo's stumbles burnish Lilly's widening lead in weight-loss drugs

With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for the Danish company's next-generation obesity drug.

Reuters • a day ago

Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan

Shares of Novo Nordisk and rival Eli Lilly fell on Tuesday after a report said price cuts are coming for the popular weight-loss drugs.

Market Watch • 16 hours ago

Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026

LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.

Zacks Investment Research • 11 hours ago

Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial

Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly's Tirzepatide in reducing body weight.

Reuters • Feb 23, 2026

Why Eli Lilly Stock Just Popped

Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply of its Zepbound tirzepatide drug.

The Motley Fool • Feb 23, 2026

Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen

The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or the multi-dose pen that delivers four weekly injections from a single device.

WSJ • Feb 23, 2026

Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug.

CNBC • Feb 23, 2026

Eli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market Crash

Eli Lilly's financial results should remain strong through economic and market downturns. The company's deep pipeline should help power growth beyond the current GLP-1 cycle.

The Motley Fool • Feb 23, 2026

Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push

Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart: a new injector pen, a new box, another reminder to refill, and one more item for the sharps bin. Eli Lilly is trying to make that routine feel less like a chore.

Invezz • Feb 23, 2026